Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
AssigneeTopigen Pharmaceutique Inc.
InventorsPaolo Renzi, Mustapha Allam, Zoulfia Allakhverdi
Life of this patent
Estimating the term…
Loading patent…
AssigneeTopigen Pharmaceutique Inc.
InventorsPaolo Renzi, Mustapha Allam, Zoulfia Allakhverdi
Estimating the term…
The invention relates to the use of nucleotide substitutes for increasing the in vivo efficacy of nucleic acid molecules and also for inhibiting inflammation in mammals. More particularly, the present invention relates to the use of 2′6′diaminopurine (DAP) and analogs thereof per se in anti-inflammatory compositions, and also for preparing nucleic acid molecules having an increased in vivo physiological efficiency and a reduced toxicity as compared to conventional oligos. The invention is particularly useful for the preparation of antisense oligonucleotides for treating pulmonary/respiratory diseases such as cystic fibrosis, asthma, chronic bronchitis, chronic obstructive lung disease, eosinophilic bronchitis, allergies, allergic rhinitis, pulmonary fibrosis, adult respiratory distress syndrome, sinusitis, respiratory syncytial virus or other viral respiratory tract infection and cancer.
A method for increasing in vivo anti-inflammatory efficacy of an oligonucleotide comprising:
Dependencies are inferred from the claim text.